StockNews.AI
JAGX
StockNews.AI
141 days

Jaguar Health Reports 2024 Financials: 2024 Net Revenue Up Approximately 20% Over 2023

1. Jaguar's revenue grew 20% in 2024 to $11.7 million. 2. Primary results from crofelemer trials expected in Q2 2025.

Earnings
-1.8%Current Return
VS
+0.47%S&P 500
$503/31 08:21 AM EDTEvent Start
$4.9104/01 03:20 PM EDTLatest Updated
3m saved
Insight
Article

FAQ

Why Bullish?

The notable revenue increase signals strong business performance, similar to successful periods in previous quarters. For example, consistent revenue growth historically supports positive stock movements.

How important is it?

The revenue growth and impending trial results are crucial for investor sentiment and JAGX's market position, suggesting a high likelihood of impacting stock performance.

Why Short Term?

Upcoming trial results and investor webcasts can create immediate interest and stock price spikes, akin to past instances when trial updates led to share increases.

Related Companies

JAGX
The total net revenue for the year ended December 31, 2024 of approximately $11.7 million for prescription and non-prescription products, including license revenue, increased approximately 20% versus net revenue of $9.8 million for the year ended December 31, 2023 The total net Q4 2024 revenue of approximately $3.5 million for prescription and non-prescription products, including license revenue, increased approximately 13% versus net Q3 2024 revenue of $3.1 million and 53% versus net Q4 2023 revenue of $2.3 million Jaguar expects first results in Q2 2025 of proof-of-concept (POC) investigator-initiated trials (IIT) of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease, with additional POC IIT results expected throughout 2025 FDA meeting in the second quarter of 2025 on the statistically significant results of the Phase 3 OnTarget trial of crofelemer in the prespecified subgroup of patients with breast cancer REMINDER: Jaguar to host investor webcast Monday, March 31st at 8:30 a.m. Eastern regarding Q4 2024 financials and company updates; Click here to register for webcast SAN FRANCISCO, CA / ACCESS Newswire / March 31, 2025 / Jaguar Health, Inc. (NASDAQ:JAGX) ("Jaguar" or the "Company") today reported consolidated financial results for the year ended December 31, 2024.

Related News